How are maternal and fetal outcomes incorporated when measuring benefits of interventions in pregnancy? Findings from a systematic review of cost-utility analyses.
Abel L. et al, (2024), Health Qual Life Outcomes, 22
Using QALYs as an outcome for assessing global prediction accuracy in diabetes simulation models
DAKIN H. et al, (2024), Medical decision making
Using orthopaedic health care resources efficiently: A cost analysis of day surgery for unicompartmental knee replacement.
Hlatshwako TG. et al, (2024), Knee, 49, 147 - 157
Estimating Risk Factor Time Paths Among People with Type 2 Diabetes and QALY Gains from Risk Factor Management.
Gao N. et al, (2024), Pharmacoeconomics
Rationing in an era of multiple tight constraints: Is cost-utility analysis still fit for purpose?
DAKIN H. and TSIACHRISTAS A., (2024), Applied Health Economics and Health Policy
Health poverty among people with type 2 diabetes mellitus (T2DM) in Malaysia.
Parra-Mujica F. et al, (2023), Soc Sci Med, 340
Trends in all-cause mortality among adults with diagnosed type 2 diabetes in West Malaysia: 2010 - 2019.
Lim L-L. et al, (2023), Diabetes Res Clin Pract, 205
Cost-effectiveness of Replacing Versus Discarding the Nail in Children with Nail Bed Injury
Dakin HA. et al, (2023), British Journal of Surgery
Effectiveness of nail bed repair in children with or without replacing the fingernail: the NINJA multicentre randomised controlled trial
JAIN A. et al, (2023), British Journal of Surgery
Cost-effectiveness of adalimumab for early-stage Dupuytren's disease : an economic evaluation based on a randomized controlled trial and individual-patient simulation model.
Dakin H. et al, (2022), Bone Jt Open, 3, 898 - 906
Cost-utility analysis of surgical fixation with Kirschner wire versus casting after fracture of the distal radius : a health economic evaluation of the DRAFFT2 trial.
Png ME. et al, (2022), Bone Joint J, 104-B, 1225 - 1233
Corrigendum: Progressive exercise compared with best-practice advice, with or without corticosteroid injection, for rotator cuff disorders: the GRASP factorial RCT.
Hopewell S. et al, (2022), Health Technol Assess, 25, 159 - 160
Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial
Nanchahal J. et al, (2022), The Lancet Rheumatology, 4, e407 - e416
Early-stage Dupuytren's disease treatment; a promising next step?
Selles R., (2022), The Lancet Rheumatology, 4, e377 - e378
Moulded cast compared with K-wire fixation after manipulation of an acute dorsally displaced distal radius fracture: the DRAFFT 2 RCT
Costa ML. et al, (2022), Health Technology Assessment, 26, 1 - 80
Lifetime cost-effectiveness simulation of once-weekly exenatide in type 2 diabetes: A cost-utility analysis based on the EXSCEL trial.
Becker F. et al, (2022), Diabetes Res Clin Pract, 183